Arresto Biosciences

Arresto Biosciences specializes in innovative digital solutions aimed at enhancing operational efficiency across multiple sectors, providing robust software platforms for advanced analytics and real-time data processing. Arresto Biosciences, founded in 2007 and headquartered in Palo Alto, US, focuses on developing digital solutions for operational efficiency. The company was sold to Gilead Sciences in December 2010 for USD 225 mn. The founder has not been specified, and no previous company information is available.

The company has successfully completed 4 deals with the most recent deal in December 2010, and has raised a total of USD 225 mn. Arresto. com offers a range of innovative digital solutions designed to enhance operational efficiency for businesses across various sectors. The company’s core product is a comprehensive software platform that integrates advanced analytics and real-time data processing capabilities, enabling clients to streamline their workflows and improve decision-making processes.

These solutions serve end users in industries such as finance, healthcare, and logistics, addressing specific challenges such as data management, compliance, and operational transparency. The platform is particularly popular among medium to large enterprises that require robust, scalable solutions. Arresto. com primarily markets its offerings in North America, Europe, and parts of Asia, catering to a diverse clientele that values technological innovation and operational optimization.

The revenue structure of arresto. com is primarily based on a subscription model, allowing clients to access its software services on a recurring basis. This model provides a steady revenue stream, as customers typically enter into annual contracts with various pricing tiers depending on their features and organization size. Arresto.

com also engages in partnerships with different industry stakeholders, thereby expanding its reach and enhancing service delivery. Clients may choose from different packages, catering to specific needs, such as basic access for smaller firms or comprehensive solutions for larger enterprises requiring advanced functionalities. This structured approach helps arresto. com maintain a competitive edge while fostering long-term client relationships.

With the recent funding from its sale to Gilead Sciences, Arresto Biosciences aims to enhance its product offerings, specifically focusing on developing new features for existing software platforms. The company plans to release these updates by the end of 2023. Additionally, Arresto is looking to expand its market presence in Asia and Europe, with targeted expansion by the end of 2024. The funding will support these initiatives, enabling growth and the introduction of innovative solutions to a broader audience.